U100 Medical Dermatology Potpourri: Challenges Faced and Lessons Learned
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
The medical literature is constantly evolving, forcing us to reconsider our practice approach. This session will highlight clinical pearls in the evaluation, treatment, and monitoring of complex medical dermatology disorders. Treatment strategies based on the latest available data in the literature will be discussed. This session is geared toward general dermatologists and residents in training.
LEARNING OBJECTIVES
Summarize latest updates and findings in the literature for medical dermatology.
Apply new concepts from the literature to the daily practice of medical dermatology.
SPEAKERS
Arash Mostaghimi, MD, MPH, FAAD
Caroline Nelson, MD, FAAD
SPEAKER DISCLOSURES
Arash Mostaghimi, MD, MPH, FAAD
AbbVie – Consultant(Fees); ACOM – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Consultant (1099 relationship)(Fees), Speaker(Fees); Digital Diagnostics – Consultant(Fees); Eli Lilly and Company – Advisory Board(Fees), Investigator(Grants/Research Funding); Equillium, Inc. – Consultant(Fees); Figure 1 Beauty, Inc. – Advisory Board(Stock); hims – Advisory Board(Stock); Incyte Corporation – Investigator(Grants/Research Funding); Olaplex – Advisory Board(Fees); Pelage Pharmaceuticals – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Fees), Consultant(Fees); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees);
Caroline Nelson, MD, FAAD
Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding);